Juvederm brochure 8 points lift
-
Upload
dokter-frodo-gaymans -
Category
Health & Medicine
-
view
3.772 -
download
3
description
Transcript of Juvederm brochure 8 points lift
the -point lift-point lift-point -point -point -point
A cl in ic ian’s guide to
Facial enhancement and rejuvenation have moved beyond wrinkle effacement
and surgical facelifts - to an approach that volumizes and structures.
This comprehensive, multimodal approach permits clinicians to develop aesthetic
treatment plans tailored to individual patient needs and designed to produce a
natural look.1
The 8-point lift is a new approach, utilizing the new VYCROSSTM collection of hyaluronic
acid (HA) dermal fi llers for facial rejuvenation and shaping. The procedure, developed
by Dr Mauricio de Maio, is delivered in 8 distinct treatment areas to achieve the most
natural result and maintain each patient’s unique facial expressions.2,3
Treatment is individualized to each patient using the Juvéderm® family of HA fi llers –
including Juvéderm® VOLBELLA® with Lidocaine, Juvéderm® VOLIFT® with Lidocaine and
Juvéderm® VOLUMA® with Lidocaine.
The procedure recommends a sequence of injection and specifi c sites that should be
adapted based on each patient’s profi le to achieve the optimal outcome. This booklet aims
to provide clinicians with the information needed to carry out the 8-point lift with confi dence.
Facial enhancement and rejuvenation
and surgical facelifts - to an approach that
This comprehensive, multimodal approach permits clinicians to develop aesthetic
Facial enhancement and rejuvenation
and surgical facelifts - to an approach that
This comprehensive, multimodal approach permits clinicians to develop aesthetic
treatment plans tailored to individual patient needs and designed to produce a 1
Facial enhancement and rejuvenation
and surgical facelifts - to an approach that
This comprehensive, multimodal approach permits clinicians to develop aesthetic
treatment plans tailored to individual patient needs and designed to produce a
Facial enhancement and rejuvenation
and surgical facelifts - to an approach that
This comprehensive, multimodal approach permits clinicians to develop aesthetic
treatment plans tailored to individual patient needs and designed to produce a
the -point lift-point lift-point lift-point lift
Volume loss and the ageing process
Volume loss and the ageing process
-HJPHS�]VS\TL�SVZZ�JVU[YPI\[LZ�ZPNUP�JHU[S`�[V�MHJPHS�HNLPUN��=VS\TL�KL�JP[Z�HYL�H�YLZ\S[�VM�[OL�SVZZ�HUK�YLWVZP[PVUPUN�VM�MHJPHS�MH[��HZ�^LSS�HZ�MYVT�ZRLSL[HS�YLTVKLSPUN�1
)`�SVVRPUN�MVY�MHJPHS�ZOHKV^Z�HUK�KLWYLZZPVUZ�^OLU�HZZLZZPUN�H�WH[PLU[��P[�PZ�WVZZPISL�[V�OLSW�PKLU[PM`�^OLYL�[OPZ�]VS\TL�OHZ�ILLU�SVZ[��;`WPJHSS �̀�[OPZ�VJJ\YZ�PU�[OL�MVSSV^PUN�HYLHZ�VM�[OL�MHJL����
Key areas of volume loss:
Tear trough and infraorbital area
*VUJH]P[`�\UKLY�[OL�L`L�HYLH�PZ�K\L�[V�JOHUNLZ�PU�ZVM[�[PZZ\L�HUK�ZRLSL[HS�Z[Y\J[\YL��;OPZ�JYLH[LZ�OVSSV^�KLWYLZZPVUZ�HUK�Å�H[[LUPUN�VM�[OL�JOLLRZ��[OH[�JHU�JVU[YPI\[L�[V^HYKZ�H�º[PYLK�SVVR»�
Nasolabial fold and the effect of gravity
3VZZ�VM�LSHZ[PJP[`�JVTIPULK�^P[O�[OL�LMMLJ[�VM�NYH]P[`�JHU�SLHK�[V�H�TVYL�WYVTPULU[�UHZVSHIPHS�MVSK�
Malar region
=VS\TL�SVZZ�PU�[OL�THSHY�YLNPVU�JVU[YPI\[LZ�[V�SVVRPUN�VSK�HUK�\U^LSS�
Mouth frown
6]LY�[PTL��[OLYL�PZ�H�SVZZ�VM�[OL�\W^HYK�[\YUPUN�VM�[OL�TV\[O�JVYULYZ�
Pre-jowl area
;OL�WYL�QV^S�KLWYLZZPVU�PZ�[OL�YLZ\S[�VM�ZHNNPULZZ��ZRPU�SH_P[`�HUK�Z\IJ\[HULV\Z�MH[�SVZZ�HUK�YLKPZ[YPI\[PVU��[OH[�NYHK\HSS`�HWWLHY�^P[O�HNLPUN�HUK�JYLH[L�H�OLH]`�HWWLHYHUJL�[V�[OL�SV^LY�MHJL�
Jawline
;OLYL�PZ�H�SVZZ�VM�KL�UP[PVU�PU�[OL�QH^SPUL�K\L�[V�HNLPUN���
*OLLR�IVUL�KL�UP[PVU�HUK�Z[Y\J[\YL
@V\[OM\S�JOLLRZ�UH[\YHSS`�OH]L�TVYL�]VS\TL�^OPJO�THRLZ�[OLT�ZTVV[O�HUK�^LSS�KL�ULK��>P[O�HNLPUN��[OPZ�`V\[OM\S�KL�UP[PVU�PZ�NYHK\HSS`�SVZ[�HZ�]VS\TL�SL]LSZ�HYL�KLWSL[LK�
Recognition of volume loss in facial ageing is the basisfor facial rejuvenation, infl uencing the types and
extent of surgical procedures, as well as the way in which minimally invasive approaches are employed.1
Restoring volume with the VYCROSSTM collection of fi llers
Enhancement of lip and
perioral areas and reduction
RI�ð�QH�OLQHV
,QGLFDWHG�IRU�ð�OOLQJ�medium-deep depressions
Restores facial volume
LQFOXGLQJ�FKHHNV��FKHHNERQH��DQG�FKLQ
94200JR 94201JR94504JR
94506JR
1 x 1 mL 2 x 1 mL1 x 2 mL
2 x 1 mL
���PJ�P/ �����PJ�P/ ���PJ�P/
Yes 0.3%
Z�Z�/LGRFDLQH(HCI)
Yes 0.3%
Z�Z�/LGRFDLQH(HCI)
Yes 0.3%
Z�Z�/LGRFDLQH(HCI)
��[���*����ú ��[���*����ú ��[���*����ú
HA fillers for use in the 8-point lift: the Juvéderm® family
+LYTHS�MPSSLYZ�OH]L�ILJVTL�H�WVW\SHY�TLHUZ�VM�HKKYLZZPUN�JVU[V\Y�KLMLJ[Z�HUK�ZVM[�[PZZ\L�H\NTLU[H[PVU�4�>P[OPU�[OL�SHZ[�KLJHKL��[OL`�OH]L�L_WVULU[PHSS`�YPZLU�PU�WVW\SHYP[`�¶�H�[YLUK�SPRLS`�[V�OH]L�ILLU�JVTWLSSLK�I`�JVUZ\TLYZ�ZLLRPUN�TPUPTHSS`�PU]HZP]L�YLQ\]LUH[PVU�WYVJLK\YLZ�[OH[�HYL�NLULYHSS`�^LSS�[VSLYH[LK�5
;OL�SH[LZ[�NLULYH[PVU�VM�1\]tKLYT®�/(�MPSSLYZ��K\L�[V�[OLPY�HK]HUJLK�[LJOUVSVN �̀�WYV]PKL�]LYZH[PSP[`�HUK�MSL_PIPSP[`�MVY�OHYTVUPV\Z�YLQ\]LUH[PVU�HUK�LUOHUJLTLU[�VM�[OL�MHJL�
Replacing volume and structure with the VYCROSSTM collection of HA fi llers
The versatility of the VYCROSSTM collection
Juvéderm® VOLBELLA® with Lidocaine
Juvéderm® VOLIFT ® with Lidocaine
Juvéderm® VOLUMA® with Lidocaine
Prod
uct
code
Pack
agin
gH
A C
once
ntra
tion
Lido
cain
e,H
Z`�V
^�
Syst
emRe
com
men
ded
Indi
catio
ns
9LVLEO\�SDUWLFXODWHNot cohesive
Smooth cohesive Smooth cohesive
HYALURONIC ACID CHAINS
HYALURONIC ACID CHAINS
HYALURONIC ACID CHAINS
2WKHU�WHFKQRORJLHV �'�PDWUL[�WHFKQRORJ\Juvéderm® 8/75$�UDQJH 9\FURVV™�WHFKQRORJ\
The Juvéderm® range of fi llersuses proprietary technology
The use of the proprietary Vycross™ technology produces malleable yet cohesive fi llers.8
NASHA technology
3D matrix technology
VYCROSSTM technology6
The VycrossTM technology provides a unique patented combination of majority low HUK�TPUVYP[`�OPNO�TVSLJ\SHY�^LPNO[�/(�MVY�TVYL�LM�JPLU[�JYVZZ�SPURPUN�YLZ\S[PUN�PU!
z�Minimal swelling, longer duration7,8 and enhanced smoothness16
Identifying patients
.H\� l Pendant cross linker l Fully reacted cross linker
SHORT CHAIN
LONG CHAIN
Identifying patients
Facial assessment and treatment planning
When approaching patients, it is important to consider how volume can accentuate the natural features.
Facial assessment
-HJPHS�HZZLZZTLU[�PU]VS]LZ�VIQLJ[P]LS`�NYHKPUN�[OL�upper, mid and lower face in terms of structure, proportion and symmetry��;OPZ�HSSV^Z�[OL�KL]LSVWTLU[�VM�H�MHJPHS�[YLH[TLU[�WSHU�[OH[�JHU�\WNYHKL�[OL�MHJL�HZ�H�^OVSL�9
7O`ZPJHS�L_HTPUH[PVU�HUK�H��WOV[VNYHWOPJ�HZZLZZTLU[���^OLYLI`�WOV[VNYHWOZ�HYL�[HRLU�MYVT�Ä�]L�KPMMLYLU[�HUNSLZ��MYVU[�]PL �̂�VISPX\L�YPNO[�HUK�SLM[��M\SS�WYVÄ�SL�YPNO[�HUK�SLM[��HUK�K\YPUN�ZP_�KPMMLYLU[�L_WYLZZPVUZ��H[�YLZ[��RPZZPUN��M\SS�ZTPSL��MYV^UPUN��YHPZPUN�IYV^Z�HUK�SLHUPUN�MVY^HYK��HYL�]LY`�\ZLM\S��HZ�P[�HSSV^Z�V]LYHSS�L]HS\H[PVU�VM�volume loss as well as facial appearance�
0THNLZ�JV\Y[LZ`�VM�+Y�+L�4HPV�HUK�(SSLYNHU��
Photographs can act as an effective tool for educating patients on their facial appearance and to explain
the rationale for the treatment plan by demonstrating the effects of ageing on the features of the face.9
Treatment planning
Facial shape and volume�OH]L�ILLU�YLJVNUPaLK�HZ�RL`�MLH[\YLZ�PU�the perception VM�`V\[OM\SULZZ�1� 0UQLJ[HISL�Ä�SSLYZ�OH]L�ZOV^U�H�reduction in the perception of a patient’s apparent age�MYVT����� �`LHYZ�10
<UKLYZ[HUKPUN�H�WH[PLU[»Z�WLYJLW[PVU�HUK�[OLPY�TV[P]H[PVUZ�HYL�[OLYLMVYL�JY\JPHS�MVY�HU�LMMLJ[P]L�[YLH[TLU[�WSHU! ���
7DNH�SKRWRV�IURP�GLIIHUHQW�DQJOHV 7DNH�SKRWRV�RI�GLIIHUHQW�IDFLDO�H[SUHVVLRQV
;OPZ�JHU�VWLU�KVVYZ�[V�V[OLY�HYLHZ[OH[�[OL�WH[PLU[�^HZ�UV[�H^HYL�VM�VY�
KPK�UV[�YLJVNUPaL�[V�IL�H�WYVISLT��0[�JHU�LUJV\YHNL�[OLT�[V�ZLL�IL`VUK�^YPURSLZ�
[V�KLLWLY�Z[Y\J[\YHS�WYVISLTZ�
Explain that as the ageing process is continual, treatment plans and goals will need to be adapted in order to optimize and maintain
desired appearance2,3
0[�PZ�OLSWM\S�[V�HJJLZZ�H�KLLWLY\UKLYZ[HUKPUN�VM�[OL�[YLH[TLU[�WSHUHUK�^OH[�HYLHZ�ZOV\SK�IL�WYPVYP[PaLK�
Develop an understanding of patients’ motivations and perceptions of beauty
(ZR�[OL�WH[PLU[!�^OH[�KV�`V\�ZLL& (ZR�[OL�WH[PLU[!�^OPJO�HYLHZ�KV�`V\�[OPUR�HYL�^VYZL�[OHU�V[OLYZ&
9LZ\S[Z�[OH[�[OL�WH[PLU[�ZOV\SK�L_WLJ[�MYVT�[OLPY�[YLH[TLU[�WSHU�ZOV\SK�IL�KPZJ\ZZLK��;OL�PTWVY[HUJL�VM�HKOLYPUN�[V�[YLH[TLU[�HUK�MVSSV^�\W�PU[LY]HSZ�ZOV\SK�IL�OPNOSPNO[LK����
Practical guide to the 8-point lift
Practical guide to the 8-point lift
;OL���WVPU[�SPM[�OHZ�ILLU�KLZPNULK�[V�WYVTV[L�H�SPM[PUN�LMMLJ[�PU�WH[PLU[Z�^OV�OH]L�SVZ[�]VS\TL�VY�KLZPYL�Z[Y\J[\YHS�LUOHUJLTLU[�[V�HJJLU[\H[L�JLY[HPU�MHJPHS�MLH[\YLZ�
Suitable for a variety
of patients†
Very little downtime
Natural result
Advantages of the 8-point lift 2,3
† 7H[PLU[Z�^P[O�ZL]LYL�ZHNNPUN�ZRPU�ZOV\SK�IL�HWWYVHJOLK�^P[O�JH\[PVU�
Important aspects to consider before treatment:
1. 1. 1. Where to injectWhere to injectWhere to inject
2.2.2. What sequence to injectWhat sequence to injectWhat sequence to inject
3.3.3. What product to injectWhat product to injectWhat product to inject
4.4.4. How much to injectHow much to injectHow much to inject
Understanding facial anatomy
)LMVYL�Z[HY[PUN�PUQLJ[PVUZ�VM�=@*96::;4��WYVK\J[Z�PU�[OL���WVPU[�SPM[�Z[YH[LN �̀�P[�PZ�L_[YLTLS`�PTWVY[HU[�[OH[�[OL�PUQLJ[VY�PZ�HWWYVWYPH[LS`�[YHPULK��;OL�PUQLJ[VY�T\Z[�OH]L�HU�L_JLSSLU[�RUV^SLKNL�VM�MHJPHS�HUH[VT �̀�PUJS\KPUN�[OL�SVJH[PVUZ�VM�ISVVK�]LZZLSZ�HUK�ULY]LZ��0U�VYKLY�[V�H]VPK�\U^HU[LK�VY�HK]LYZL�LMMLJ[Z��PUQLJ[PVUZ�T\Z[�H]VPK�PUQ\Y`�[V�ULY]LZ�HUK�ZOV\SK�UV[�IL�THKL�PU[V�ISVVK�]LZZLSZ��;OLYLMVYL��HZWPYH[L�ILMVYL�PUQLJ[PUN�/(�[V�KL[LJ[�HU`�WYLZLUJL�VM�ISVVK�HZ�P[�^PSS�PUKPJH[L�PU[YH]HZJ\SHY�PUQLJ[PVU��0M�`V\�KL[LJ[�ISVVK��PTTLKPH[LS`�Z[VW�PUQLJ[PUN��^P[OKYH^�[OL�ULLKSL��JVTWYLZZ�HUK�JOVVZL�H�KPMMLYLU[�PUQLJ[PVU�ZP[L��(Z�LHJO�WLYZVU»Z�HUH[VT`�JHU�IL�ZSPNO[S`�KPMMLYLU[��JHYLM\S�PUZWLJ[PVU�VM�LHJO�WH[PLU[»Z�MHJL�PZ�ULJLZZHY`�MVY�[OLZL�]HZJ\SHY�Z[Y\J[\YLZ��
Practical guide to the 8-point lift
)RU�LOOXVWUDWLYH�SXUSRVHV�RQO\��Variations in anatomy exist and can differ from patient to patient.
Nerves
Muscle
1� -YVU[HSPZ�T�
2� ;LTWVYHSPZ�T�
3� *VYY\NH[VY�T�
4� 5HZHSPZ�T�
5 Levator labii � Z\WLYPVYPZ�T�
6� A`NVTH[PJ\Z�TPUVY�T�
7� A`NVTH[PJ\Z�THQVY�T�
8� +LWYLZZVY�ZLW[P�T�
9� 9PZVYP\Z�T�
10� 6YIPJ\SHYPZ�VYPZ�T�
11� +LWYLZZVY�HUN\SP�VYPZ�T�
12� +LWYLZZVY�SHIPP�� PUMLYPVYPZ�T�
13� 4LU[HSPZ�T�
14� 7YVJLY\Z�T�
15� 6YIPJ\SHYPZ�VJ\SP�T�
16� 7HYV[PK�NSHUK
17� )\JJHS�MH[�WHK
18� 4HZZL[LY�T�
19� :\ITHUKPI\SHY�� ZHSP]HY`�NSHUK�
20� 7SH[`ZTH�T�
1� :\WYHVYIP[HS�U��� �TLKPHS�IYHUJO�
2� :\WYHVYIP[HS�U��� �SH[LYHS�IYHUJO�
3� :\WYH[YVJOSLHY�U�
4� 0UMYH[YVJOSLHY�U�
5� 3HJYPTHS�U�
6� ,_[LYUHS�UHZHS�U�
7� 0UMYHVYIPHS�U�
8� )\JJHS�IYHUJO�VM�� MHJPHS�U�
9� 4LU[HS�U�
1� :\WYHVYIP[HS�H�
2� :\WYHVYIP[HS�]�
3� :\WLY�JPHS�[LTWVYHS�H��� �� �MYVU[HS�IYHUJO�
4� :\WLY�JPHS�[LTWVYHS�]��� �� �MYVU[�IYHUJO�
5� :\WYH[YVJOSLHY�H�
6� :\WYH[YVJOSLHY�]�
7� 0UMYHVYIP[HS�H�
8� 0UMYHVYIP[HS�]�
9� -HJPHS�]�
10� -HJPHS�H�
11� 4LU[HS�]�
12� 4LU[HS�H�
13� :\ITLU[HS�H�
14� :\ITLU[HS�]�
15� ,_[LYUHS�JHYV[PK�H�
1
2
3
4
5
6
7
8
9
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Anatomy of the face11,12
� :\WLY�JPHS�[LTWVYHS�H��� �
� :\WLY�JPHS�[LTWVYHS�]��� �
Circulation
4
5
1
2
6
7
8
9
10
11
12
13
14
15
3
Practical guide to the 8-point lift
;YLH[TLU[�VM�[OL�JOLLRIVULZ�^P[O�]VS\TL�TH`�PTWYV]L�[OL�HWWLHYHUJL�VM�[OL�UHZVSHIPHS�MVSK�HUK�ZOVY[LU�[OL�SPK�JOLLR�Q\UJ[PVU���
;OPZ�JSLHYS`�ZOV^Z�PTWYV]LTLU[�PU�HU�HYLH�[OH[�OHZ�UV[�ILLU�KPYLJ[S`�PUQLJ[LK��53-�VY�[LHY�[YV\NO��I`�PUQLJ[PUN�PU[V�P[Z�ULPNOIV\YPUN�HYLH��JOLLRIVUL�VY�TPK�JOLLR�����
;OYV\NO�\UKLYZ[HUKPUN�VM�[OPZ�YH[PVUHSL��[OL�[YLH[TLU[�VM�[OL�QH^SPUL��WYL�QV^S�Z\SJ\Z�HUK�THYPVUL[[L�SPULZ�ZOV\SK�Z[HY[�PU�[OL�\WWLY�TPK�MHJL�HSVUN�[OL�a`NVTH[PJ�HYJO�HUK�JOLLRIVULZ����
1.1.1. Where to inject? Where to inject? Where to inject?
>OLU�L]HS\H[PUN�[OL�HYLHZ�[V�PUQLJ[��P[�PZ�PTWVY[HU[�[V�YLTLTILY�[OH[�JYLH[PUN�Z[Y\J[\YL�HUK�]VS\TL�PU�VUL�HYLH�VM�[OL�MHJL�TH`�SLHK�[V�PTWYV]LTLU[�PU�HUV[OLY��HKQHJLU[�WHY[����
0THNL�JV\Y[LZ`�VM�+Y�+L�4HPV�HUK�(SSLYNHU��0THNL�JV\Y[LZ`�VM�+Y�+L�4HPV�HUK�(SSLYNHU��
,_WSHUH[PVUZ�MVY�LHJO�WVPU[�HYL�HZ�MVSSV^Z!
Point 1: Zygomatic arch 3PM[PUN�WVPU[�VM�SH[LYHS�JOLLRIVUL��0[�PZ�[OL��YZ[�HUJOVYPUN�WVPU[��HUK�YLK\JLZ�[OL�]VS\TL�YLX\PYLTLU[�VM�WVPU[Z���HUK���
Point 2: Cheekbone7YVQLJ[PVU�VM�JOLLRIVULZ�HUK�ZOVY[LUPUN�VM�WHSWLIYHS�THSHY�Z\SJ\Z�
Point 3: Mid-cheek region0TWYV]LTLU[�VM�[OL�TLKPHS�SPK�JOLLR�Q\UJ[PVU�HUK�JVUZLX\LU[�ZVM[LUPUN�VM�[OL�[LHY�[YV\NO��
Point 4: Canine fossa and nasolabial fold3LZZ�]VS\TL�PZ�ULLKLK�HM[LY�HYLHZ������HUK���HYL�[YLH[LK��
Point 5: Marionette lines:[HY[�MYVT�[VW�[V�IV[[VT�[V�Z[YLUN[OLU�HUK�SPM[�[OL�T\JVZH�VM�[OL�VYHS�JVTTPZZ\YL��
Point 6: Pre-jowl sulcus:THSS�IVS\Z�VY�SPULHY�YL[YVNYHKL�[LJOUPX\LZ�HYL�Z\P[HISL�OLYL��+V�UV[�PUQLJ[�[OL�QV^SZ��
Point 7: Jawline3PULHY�HUK�YL[YVNYHKL�[LJOUPX\L�PZ�WYLMLYHISL�H[�[OPZ�SL]LS��7VZ[�QV^S��THUKPISL�IVK`�HUK�HUNSL�TH`�IL�PUQLJ[LK��
Point 8: Sub-malar region(KKYLZZLZ�[OL�Z\URLU�HYLH�H[�[OPZ�ZP[L�HUK�HSZV�JVTWYPZLZ�[OL�Z\I�THSHY�]VS\TL�SVZZ��0[�PZ�HUJPSSHY`�[V�[OL�SPM[PUN�LMMLJ[��)VS\Z�VY�MHU�PUQLJ[PVU�[LJOUPX\L�^PSS�KLWLUK�VU�[OL�ZPaL�VM�[OL�HYLH��
;OL�ZLX\LUJL�VM�PUQLJ[PVU�HUK�ZWLJPÄ�J�ZP[LZ�ZOV\SK�IL�HKHW[LK�IHZLK�VU�LHJO�WH[PLU[»Z�WYVÄ�SL�[V�HJOPL]L�[OL�VW[PTHS�V\[JVTL�
2.2.2. What is the best sequence of injections for your patient? What is the best sequence of injections for your patient? What is the best sequence of injections for your patient? 2,32,32,3
;OL�WVZP[PVU�HUK�ZLX\LUJL�VM�[OL�PUQLJ[PVUZ�PZ�ZOV^U�PU�[OL�WOV[VNYHWO��:THSS�IVS\Z�PUQLJ[PVUZ�PU�[OLZL�ZP[LZ�^PSS�HUJOVY�HUK�IYPUN�Z\WWVY[�[V�[OL�MHJL��)`�PUQLJ[PUN�PU�[OL�ZLX\LUJL�ZOV^U��[OL�]VS\TL�VM�WYVK\J[�\ZLK�JHU�IL�TPUPTPZLK��`L[�Z[PSS�HJOPL]L�TH_PT\T�LMMLJ[�
2
1
7
48
3
6
5
Practical guide to the 8-point lift
First direct thepatient to lean forward (eyes up, chin down)
so as to demarcate the GO/NO GO areas
prior to injecting.
In addition to Juvéderm® VOLUMA® with Lidocaine and Juvéderm® VOLIFT® with Lidocaine used in the 8-point lift,
Juvéderm® VOLBELLA® with Lidocaine can also be used
to treat the lip, peri-oral and peri-orbital
areas if desired.
Where NOT to inject 2,3
7H[PLU[Z�^P[O�ZL]LYL�ZHNN`�ZRPU�ZOV\SK�IL�PUQLJ[LK�^P[O�JH\[PVU��(U`�WYVK\J[�PUQLJ[LK�PU[V�[OL�NO GO HYLHZ��YLK�JPYJSLZ��TH`�SLHK�[V�^VYZLUPUN�VM�[OL�MVSK�VY�ZHNNPULZZ��;OLZL�HYL�[OL�HYLHZ�[OH[�^VYZLU�HUK�MVSK�^OLU�[OL�WH[PLU[�SLHUZ�MVY^HYK��
The NO GO areas
;OL�IS\L�JPYJSLZ�PU�[OL�KPHNYHT�HYL�[OL�HYLHZ�[V�PUQLJ[�PU�[OL���WVPU[�Z[YH[LN`!�[OL�GO�HYLHZ��
The GO areas
0THNLZ�JV\Y[LZ`�VM�+Y�+L�4HPV�HUK�(SSLYNHU��
0THNLZ�JV\Y[LZ`�VM�+Y�+L�4HPV�HUK�(SSLYNHU�
PointPointPoint ProductsProductsProducts
1.1.1. Zygomatic archZygomatic archZygomatic arch JuvédermJuvédermJuvéderm®®® VOLUMA VOLUMA VOLUMA® ® ® VOLUMA® VOLUMA VOLUMA VOLUMA® VOLUMA® VOLUMA® VOLUMA VOLUMA VOLUMA® VOLUMA with Lidocainewith Lidocainewith Lidocaine
2.2.2. CheekboneCheekboneCheekbone JuvédermJuvédermJuvéderm®®® VOLUMA VOLUMA VOLUMA
® ® ® with Lidocainewith Lidocainewith Lidocaine
3.3.3. Mid-cheek regionMid-cheek regionMid-cheek region JuvédermJuvédermJuvéderm®®® VOLUMA VOLUMA VOLUMA
® ® ® with Lidocainewith Lidocainewith Lidocaine
4.4.4. Nasolabial foldsNasolabial foldsNasolabial folds JuvédermJuvédermJuvéderm®®® VOLIFT VOLIFT VOLIFT
® ® ® with Lidocainewith Lidocainewith Lidocaine
5.5.5. Marionette lines (mouth frown)Marionette lines (mouth frown)Marionette lines (mouth frown) JuvédermJuvédermJuvéderm®®® VOLIFT VOLIFT VOLIFT
® ® ® with Lidocainewith Lidocainewith Lidocaine
6.6.6. Pre-jowl areaPre-jowl areaPre-jowl area JuvédermJuvédermJuvéderm®®® VOLUMA VOLUMA VOLUMA
® ® ® with Lidocainewith Lidocainewith Lidocaine
7.7.7. JawlineJawlineJawline JuvédermJuvédermJuvéderm®®® VOLUMA VOLUMA VOLUMA
® ® ® with Lidocainewith Lidocainewith Lidocaine
8.8.8. Cheek regionCheek regionCheek region JuvédermJuvédermJuvéderm®®® VOLUMA VOLUMA VOLUMA
® ® ® with Lidocainewith Lidocainewith Lidocaine
3.3.3. Which products to inject and where Which products to inject and where Which products to inject and where
BEFORE AFTER
Practical guide to the 8-point lift
4.4.4. How much to inject? How much to inject? How much to inject?
;OL�HTV\U[�PUQLJ[LK�WLY�WVPU[�^PSS�]HY`�MYVT�WH[PLU[�[V�WH[PLU[��KLWLUKPUN�VU�[OL�WH[PLU[»Z�ULLK��KLNYLL�VM�]VS\TL�SVZZ�HUK�IVUL�Z[Y\J[\YL��
@V\UNLY�WH[PLU[Z�^P[O�TPSK�[V�TVKLYH[L�ZHNNPUN�TH`�ULLK�H�[V[HS�PUQLJ[PVU�]VS\TL�VM�HWWYV_PTH[LS`���T3�VM�1\]tKLYT®�=63<4(® ^P[O�3PKVJHPUL��6SKLY�WH[PLU[Z�^P[O�TVYL�ZL]LYL�]VS\TL�KLÄ�JPLUJ`�TH`�ULLK���T3�VY�TVYL��5V�TVYL�[OHU�����T3�ZOV\SK�IL�PUQLJ[LK�WLY�WVPU[�
The following patient case studies provide an example of volumes that may be injected at each point
7VPU[��!�����T3�7VPU[��!�����T37VPU[��!�����T37VPU[��!������T3�
7VPU[��!������T37VPU[��!������T37VPU[��!������T3
;V[HS�PUQLJ[PVU�]VS\TL!�
$GDSWHG�IURP�'H�0DLR�&DVH�6WXG\B$VLD�3DFLð�F13
7VPU[��!�����T3�7VPU[��!�����T37VPU[��!�����T37VPU[��!�����T3
7VPU[��!�����T37VPU[��!�����T3�7VPU[��!�����T37VPU[��!�����T3�
;V[HS�PUQLJ[PVU�]VS\TL!�
Adapted from De Maio M. 20122�DQG�'H�0DLR��5]DQ\3
;OLZL�HYL�L_HTWSL�WH[PLU[�JHZL�Z[\KPLZ�HUK�UV[�H�WYLJPZL�YLJVTTLUKH[PVU�
Scheduling treatments
9LZ\S[Z�HYL�ILZ[�L]HS\H[LK�H[�^LLR���HUK�^LLR����0[�PZ�[OLYLMVYL�YLJVTTLUKLK�[OH[�WH[PLU[Z�HYL�PU]P[LK�[V�JVTL�IHJR�MVY�HU�HZZLZZTLU[�K\YPUN�[OPZ�[PTL�WLYPVK��MVSSV^LK�I`�M\Y[OLY�JVUZ\S[H[PVUZ�H[������TVU[OZ�PU[LY]HSZ��;OPZ�^PSS�OLSW�[V�THPU[HPU�HU�VW[PTHS�SVVR�HUK�LZ[HISPZO�HU`�ULLK�MVY�M\Y[OLY�LUOHUJLTLU[�VY�V[OLY�HLZ[OL[PJ�WYVK\J[Z�
Explain that as the ageing process is continual, treatment plans and goals will need to change in order
to optimize and maintain desired appearance
For you and your patient
;OL���^LLRZ�MVSSV^PUN�[YLH[TLU[�HYL�PTWVY[HU[��;V�H]VPK�IHJ[LYPHS�contamination14��KPYLJ[�`V\Y�WH[PLU[�[V!
z�4PUPTPZL�[V\JOPUN�[OL�PUQLJ[PVU�ZP[LZ14
z�(]VPK�THRL�\W�MVY����OV\YZ15
z�0KLHSS �̀�H]VPK�M\Y[OLY�[YLH[TLU[Z�PU�[OPZ�HYLH�MVY���KH`Z14
z�*VU[HJ[�`V\�\WVU�[OL�HWWLHYHUJL�VM�\U\Z\HS�Z`TW[VTZ
3OHDVH�UHIHU�WR�WKH�')8�VXSSOLHG�ZLWK�HDFK�SURGXFW�IRU�DGGLWLRQDO�LQIRUPDWLRQ�
2
1
7
48
3
6
5
5.5.5. Post-injection guidelines Post-injection guidelines Post-injection guidelines
1.�/VMMTHUU�2��)4*�+LYTH[VSVN`����� "9!�� ��2.�+L�4HPV�4�� BHIZ[YHJ[D�� 0U!�7YVNYHTTL�HUK�(IZ[YHJ[Z��)LH\[`�;OYV\NO�:JPLUJL�� 0U[LYUH[PVUHS�(LZ[OL[PJ�:`TWVZP\T�:[VJROVST��������3.�+L�4HPV�4�� �9aHU`�)���PU�WYLZZ��̧ ;OL���WVPU[�SPM[¹��0UQLJ[HISL�-PSSLYZ�PU�(LZ[OL[PJ�4LKPJPUL���UK�LK���¶�:WYPUNLY��4.�3\LIILYKPUN�:�� �(SL_PHKLZ�(YTLUHRHZ�4��1��+Y\NZ�+LYTH[VS������"11� �!�����������5.�.PSILY[�,��L[�HS��1�+Y\NZ�+LYT[VS������"11� �!��� �������6.�7H[LU[�VU�[OL�WVS`TLYPaH[PVU�VM� [OL� SV^� HUK� OPNO�TVSLJ\SHY�^LPNO[� WVS`ZHJJOHYPKLZ�<:������ � ��� 7.� ,JJSLZ[VU�+�� �4\YWO`�+2��*SPU� *VZTL[� 0U]LZ[PN� +LYTH[VS�� ����"5!���������8.�9HZWHSKV�/��1��*VZTL[�3HZLY�;OLY������"10�!���������9.�+L�4HPV�,_WLY[�0UZPNO[Z�K\YPUN�^VYRZOVWZ��10.�;H\I�(-��L[�HS��+LYTH[VS�:\YN� ����"36���!���������11.�,UKVZJVWPJ�7SHZ[PJ�:\YNLY`��)VZ[^PJR��,H]LZ�5HOHP���Z[�LKP[PVU��12.�*SLTLU[L�(UH[VT`���(�9LNPVUHS�([SHZ�VM�[OL�/\THU�)VK`���[O�LKP[PVU��13.�+H[H�VU�Ä�SL��+L�4HPV�*HZL�:[\K`F(ZPH�7HJPÄ�J��14.�4VUOLP[�.+�� �9VOYPJO�91��+LYTH[VS�:\YN���� "35�:\WWS��!�� ��������15.�1<=i+,94®�=63),33(®�^P[O�3PKVJHPUL�+-<�B+PYLJ[PVUZ�MVY�<ZLD��9L]PZPVU��������� �����+-<Z�HYL�H]HPSHISL�PUZPKL�[OL�WYVK\J[�IV_�VY�MYVT�`V\Y�SVJHS�(SSLYNHU�YLWYLZLU[H[P]L��16. Allergan Data on -PSL��4PJYVZJVWPJ�VIZLY]H[PVUZ�MVY�Ä�SSLY�WYVK\J[Z�
1.�/VMMTHUU�2��)4*�+LYTH[VSVN`����� "9!�� ��2.�+L�4HPV�4�� BHIZ[YHJ[D�� 0U!�7YVNYHTTL�HUK�(IZ[YHJ[Z��)LH\[`�;OYV\NO�:JPLUJL�� 0U[LYUH[PVUHS�(LZ[OL[PJ�:`TWVZP\T�:[VJROVST��������3.�+L�4HPV�4�� �9aHU`�)���PU�WYLZZ��̧ ;OL���WVPU[�SPM[¹��0UQLJ[HISL�-PSSLYZ�PU�(LZ[OL[PJ�4LKPJPUL���UK�LK���¶�:WYPUNLY��4.�3\LIILYKPUN�:�� �(SL_PHKLZ�(YTLUHRHZ�4��1��+Y\NZ�+LYTH[VS������"11� �!�����������5.�.PSILY[�,��L[�HS��1�+Y\NZ�+LYT[VS������"11� �!��� �������6.�7H[LU[�VU�[OL�WVS`TLYPaH[PVU�VM� [OL� SV^� HUK� OPNO�TVSLJ\SHY�^LPNO[� WVS`ZHJJOHYPKLZ�<:������ � ��� 7.� ,JJSLZ[VU�+�� �4\YWO`�+2��*SPU� *VZTL[� 0U]LZ[PN� +LYTH[VS�� ����"5!���������8.�9HZWHSKV�/��1��*VZTL[�3HZLY�;OLY������"10�!���������9.�+L�4HPV�,_WLY[�0UZPNO[Z�K\YPUN�^VYRZOVWZ��10.�;H\I�(-��L[�HS��+LYTH[VS�:\YN� ����"36���!���������11.�,UKVZJVWPJ�7SHZ[PJ�:\YNLY`��)VZ[^PJR��,H]LZ�5HOHP���Z[�LKP[PVU��12.�*SLTLU[L�(UH[VT`���(�9LNPVUHS�([SHZ�VM�[OL�/\THU�)VK`���[O�LKP[PVU��13.�+H[H�VU�Ä�SL��+L�4HPV�*HZL�:[\K`F(ZPH�7HJPÄ�J��14.�4VUOLP[�.+�� �9VOYPJO�91��+LYTH[VS�:\YN���� "35�:\WWS��!�� ��������15.�1<=i+,94®�=63),33(®�^P[O�3PKVJHPUL�+-<�B+PYLJ[PVUZ�MVY�<ZLD��9L]PZPVU��������� �����+-<Z�HYL�H]HPSHISL�PUZPKL�[OL�WYVK\J[�IV_�VY�MYVT�`V\Y�SVJHS�(SSLYNHU�YLWYLZLU[H[P]L��16. Allergan Data on -PSL��4PJYVZJVWPJ�VIZLY]H[PVUZ�MVY�Ä�SSLY�WYVK\J[Z�
A new�^OVSL�MHJL�HWWYVHJO�MVY�MHJPHS�YLQ\]LUH[PVU�HUK�LUOHUJLTLU[�\ZPUN�the VYCROSSTM collection
Juvéderm® VOLUMA® with Lidocaine
Juvéderm® VOLIFT ® with Lidocaine
Juvéderm® VOLBELLA® with Lidocaine
�^OVSL�MHJL�HWWYVHJO�MVY�MHJPHS�YLQ\]LUH[PVU�HUK�LUOHUJLTLU[�\ZPUN�the VYCROSS
® VOLUMAJuvéderm® VOLIFT
VOLBELLA
�^OVSL�MHJL�HWWYVHJO�MVY�MHJPHS�YLQ\]LUH[PVU�HUK�LUOHUJLTLU[�\ZPUN�the VYCROSS
VOLUMA VOLIFT ®
VOLBELLA
�^OVSL�MHJL�HWWYVHJO�MVY�MHJPHS�YLQ\]LUH[PVU�HUK�LUOHUJLTLU[�\ZPUN�the VYCROSS
® VOLUMA® VOLIFT ®
VOLBELLA
the -point -point -point -point lift lift-point lift-point
7YLWHYH[PVU�+H[L�(WYPS�����)53����������